Skip to main content
Clinical Trials/JPRN-UMIN000018813
JPRN-UMIN000018813Completed未知

a study on SDI-DLB concerning to diagnose DLB and assess benefit for Donepezil : Study 2 - SDI-DLB: diagnose DLB and assess benefit for Donepezil(Study 2)

Promedico Co., Ltd.0 sites30 target enrollmentStarted: August 28, 2015Last updated:
Conditions

Trial Snapshot

Phase
未知
Status
Completed
Sponsor
Enrollment
30

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
60years-old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1)dozed antidementia drugs except Donepezil within 12 weeks before informed consent 2)bed ridden 3)with severe impairment of visual acuity, auditory sensor and/or communication 4)with neurological degenerative disease except for DLBV criteria, schizophrenia, bipolar disorder and major depression 5)with delirium due to abuse of alcohol, drugs, metabolic toxicity and inflammation 6)inadequate decided by principal investigator 7)with hypersensitivity to components of Donepezil or piperidine derivative 8)dozed investigational drug within 12 weeks before informed consent

Investigators

Sponsor
Promedico Co., Ltd.

Similar Trials